Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

43.24USD
22 Aug 2014
Price Change (% chg)

$0.10 (+0.23%)
Prev Close
$43.14
Open
$43.08
Day's High
$43.34
Day's Low
$42.54
Volume
507,782
Avg. Vol
744,387
52-wk High
$54.25
52-wk Low
$29.36

ALKS.O

Chart for ALKS.O

About

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. The Company manufactures... (more)

Overall

Beta: 1.16
Market Cap (Mil.): $6,305.60
Shares Outstanding (Mil.): 145.83
Dividend: --
Yield (%): --

Financials

  ALKS.O Industry Sector
P/E (TTM): -- 142.68 34.50
EPS (TTM): -0.07 -- --
ROI: -0.65 -2.89 17.96
ROE: -0.88 -7.11 18.65
Search Stocks

Even with Irish address, Alkermes prefers independence

SAN DIEGO - Dublin, Ireland-based Alkermes Plc has the low-tax domicile currently in vogue among multinational pharmaceutical companies but is not interested in being bought out as it nears the launch of new drugs, its chief executive said on Monday.

23 Jun 2014

Alkermes to seek schizophrenia drug approval after trial success

- Alkermes Plc said it planned to seek U.S. marketing approval for its experimental drug to treat the symptoms of schizophrenia after it succeeded in a late-stage study, sending the company's shares up as much as 11 percent.

08 Apr 2014

UPDATE 3-Alkermes to seek schizophrenia drug approval after trial success

* To apply for U.S. marketing approval in the third quarter

08 Apr 2014

CORRECTED-UPDATE 1-Alkermes' schizophrenia drug meets main goal of late-stage study

(Corrects to remove paragraphs referring to Alzheimer's disease. Alkermes' drug is not used to treat Alzheimer's)

08 Apr 2014

Alkermes' schizophrenia drug meets main goal of late-stage study

April 8 - Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study.

08 Apr 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks